Yaacoub Carole, Wehbe Rim, Roufayel Rabih, Fajloun Ziad, Coutard Bruno
Unité des Virus Emergents, Aix-Marseille University, IRD 190-Inserm 1207, IHU Méditerranée Infection, 13005 Marseille, France.
Laboratory of Applied Biotechnology (LBA3B), Azm Center for Research in Biotechnology and Its Applications, Doctoral School for Sciences and Technology, Lebanese University, Tripoli 1300, Lebanon.
Pathogens. 2023 Nov 15;12(11):1354. doi: 10.3390/pathogens12111354.
Viruses are known to infect most types of organisms. In humans, they can cause several diseases that range from mild to severe. Although many antiviral therapies have been developed, viral infections continue to be a leading cause of morbidity and mortality worldwide. Therefore, the discovery of new and effective antiviral agents is desperately needed. Animal venoms are a rich source of bioactive molecules found in natural goods that have been used since ancient times in alternative medicine to treat a variety of human diseases. Recently, and with the onset of the COVID-19 pandemic, scientists have regained their interest in the possible use of natural products, such as bee venom (BV), as a potential antiviral agent to treat viral infections. BV is known to exert many therapeutic activities such as anti-proliferative, anti-bacterial, and anti-inflammatory effects. However, there is limited discussion of the antiviral activity of BV in the literature. Therefore, this review aims to highlight the antiviral properties of BV and its two primary constituents, melittin (MEL) and phospholipase A2 (PLA2), against a variety of enveloped and non-enveloped viruses. Finally, the innovative strategies used to reduce the toxicity of BV and its two compounds for the development of new antiviral treatments are also considered.
众所周知,病毒可感染大多数类型的生物体。在人类中,它们可引发多种疾病,从轻微到严重不等。尽管已经开发出许多抗病毒疗法,但病毒感染仍是全球发病和死亡的主要原因。因此,迫切需要发现新的有效抗病毒药物。动物毒液是天然产物中生物活性分子的丰富来源,自古以来就被用于替代医学治疗各种人类疾病。最近,随着新冠疫情的爆发,科学家们重新对天然产物如蜂毒(BV)作为治疗病毒感染的潜在抗病毒药物的可能用途产生了兴趣。已知BV具有许多治疗活性,如抗增殖、抗菌和抗炎作用。然而,文献中对BV抗病毒活性的讨论有限。因此,本综述旨在突出BV及其两种主要成分蜂毒肽(MEL)和磷脂酶A2(PLA2)对多种包膜病毒和非包膜病毒的抗病毒特性。最后,还考虑了用于降低BV及其两种化合物的毒性以开发新的抗病毒治疗方法的创新策略。